NANOBIOTIX Stock: 24.99% Decline Over the Week Despite Clinical Catalysts
NANOBIOTIX stock ended Thursday, October 23, with a decrease of 7.70%, at €17.74, extending a more pronounced correction over the last seven days. Following positive clinical data announcements in September, the stock is undergoing a bearish consolidation phase that partially erases the impressive gains accumulated over three months. Meanwhile, the CAC 40 index slightly increased by 0.23% during the same session, highlighting the stock's underperformance compared to the overall market.
Weekly Performance and Market Reactions
The stock, which closed at €19.22 on Wednesday, October 22, settled at €17.74 at the end of Thursday, representing a clear downward movement and limiting trading to 1.85% of the capital. Over the past week, NANOBIOTIX has seen a decline of 24.99%, erasing a significant portion of the exceptional performance recorded earlier. However, the performance remains well-oriented in the medium term: the stock has gained 315% since the beginning of 2025 and 289% since the same day in 2024, far exceeding the modest progression of the CAC 40 at +9.17% annually. This heightened volatility reflects the cyclothymic nature of biotechnological stocks, highly sensitive to clinical results publications and regulatory developments. Capital turnover indicators signal intermediate-sized trades, reflecting sustained market participant interest. The five-day price swing of -24.99% reveals a pronounced dispersion of shareholder expectations regarding the company's business prospects.
Recent Developments and Strategic Partnerships
NANOBIOTIX's recent trajectory is set against a backdrop marked by the announcement of positive clinical data for NBTXR3, its leading drug candidate. These results were communicated on September 17, 2025, for the treatment of primary cutaneous melanoma in second-line therapy or beyond. The product, marketed under the brand Hensify® in Europe for soft tissue sarcomas, is based on a revolutionary approach that involves physical activation by radiotherapy. The company continues to develop NBTXR3 through a partnership established with Johnson & Johnson in 2023, which was restructured in March 2025. Under the current terms, the group may receive approximately $2.6 billion in potential milestone payments as well as double-digit royalties ranging from 10 to 20%. These milestones include payments linked to positive data and regulatory approvals expected particularly for squamous cell carcinoma of the head and neck. NANOBIOTIX has sufficient cash to fund its operations until the second quarter of 2026, benefiting from the majority of phase 3 trial financing being covered by its American partner.
Technical Analysis and Market Indicators
From a technical standpoint, the Relative Strength Index stands at 57, indicating a neutral position without a clear direction. The MACD, which compares short and medium-term exponential moving averages, shows a slightly negative signal at -0.50, while its line is positioned at 2.72 against 3.23 for the signal line. The moving averages reveal a smoothed bullish structure: the MM50 extends to €12.83 while the MM200 is established at €6.06, a difference of €6.60 demonstrating a structural shift in the stock. However, the stock is now trading around this MM50, suggesting a phase of friction. The Bollinger Bands place the course between €12.12 as the lower support and €27.04 as the upper resistance, offering a movement range of nearly €15. The ATR index of €1.18 indicates moderate intraday volatility, while the technical support threshold is evaluated at €7.95 and the resistance at €24.45.
